After initiating a wind-down more than 18 months ago and exploring liquidation, Galera Therapeutics has found a path forward ...

A slow start to 2026 has put first-time biotech financings on course for their worst year since before the pandemic, reducing ...

Smaller acquisitions and disciplined pricing are proving to be big benefits to a wider number of companies ...

The high-profile obesity drug developer priced the biotech sector’s biggest offering since 2022 and will use the proceeds to ...

Seaport Therapeutics, a Boston biotech led by Daphne Zohar, has filed to go public, setting up a Nasdaq debut that could funnel fresh cash into its neuropsychiatric drug pipeline. Spun out of PureTech ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

-- PanGIA Analysis System, a novel machine learning platform for non-invasive diagnosis of oral cancer through an oral sample -- PanGIA Analysis System, a novel machine learning platform for ...

Companies have long lamented Europe's fragmented capital markets, single-market adoption on pricing and clinical trials, and ...

For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...

Biogen could see lower royalties for Ocrevus after its patent expires , but it has developed other medicines that will ...

Xtalks is pleased to announce its role as an official Media Partner for the Toronto Life Sciences and Biotech Summit, taking ...

In this article, we will be taking a look at the 10 Best Biotech Stocks Under $10 to Buy. According to Eli Casdin, CEO of ...